CVS vs. Amazon: Healthcare Battle Continues- Which Stock to Buy Now?

CVS Health is experiencing a robust comeback in 2025, emerging as a top 10 S&P 500 performer with a 56% year-to-date gain, driven by its vertically integrated ecosystem, including 9,000+ retail locations, Aetna, and Oak Street Health, which generated $95 billion in Q1 2025 revenue. This contrasts with Amazon's more modest 1.8% YTD rise, as Amazon pursues a digital-first, AI-powered healthcare strategy through One Medical and AWS. Despite Amazon's innovative approach, CVS's established physical footprint and integrated care model are currently yielding superior market performance and a more attractive valuation (10.48x forward P/E vs. Amazon's 33.3x), positioning CVS as the preferred investment for near-term earnings prospects.

Analysis

CVS Health is demonstrating significant momentum in 2025, positioning itself as a top 10 S&P 500 performer with a 56% year-to-date stock gain, starkly outperforming Amazon's 1.8% rise and the S&P 500's 5.1% increase. This recovery follows a challenging 2024 and is propelled by the successful execution of its vertically integrated strategy, which combines its vast retail footprint of over 9,000 locations, the Aetna insurance arm, and Oak Street Health clinics. This model is yielding tangible results, such as a 3% reduction in medical costs for Medicare Advantage members who utilize CVS pharmacies. In contrast, Amazon is pursuing a modular, technology-first disruption strategy, leveraging AWS, generative AI to reduce physician administrative time by 40% in its One Medical clinics, and its logistics network for new ventures like at-home diagnostics. Despite similar forward EPS growth projections for 2025 (12.7% for CVS vs. 12.5% for AMZN), a significant valuation gap exists; CVS trades at an attractive 10.48x forward P/E, while Amazon commands a much higher 33.3x multiple, suggesting CVS currently offers a more compelling risk-reward profile based on demonstrated execution.

Key Decisions for Investors

• Given CVS's significant stock outperformance, strong execution of its integrated care model, and a favorable valuation at 10.48x forward P/E, investors may view it as a primary vehicle for exposure to the healthcare services sector.
• For Amazon, its healthcare initiatives represent a long-term, higher-risk growth option; investors should monitor the scalability and profitability of its tech-driven ventures like One Medical and AWS HealthScribe before committing new capital based on this vertical alone.
• Consider that CVS presents a value and execution-driven play, while Amazon offers a high-multiple bet on technological disruption; portfolio allocation between the two should reflect an investor's tolerance for near-term performance versus long-term, speculative growth.